Eli Lilly - NYSE:LLY
Earnings
Rep: $2.49 ✅ Exp: $2.29 - 8.45% HIGHER
Revenue
Rep: $9.35b ✅ Exp: $8.94b - 4.55% HIGHER
Company Summary
Eli Lilly is the worlds 9th largest company by market cap at $670b and they have reported positive earnings and revenue both coming in higher than expected for Q4 2023. The pharmaceutical giant booked fourth-quarter...
Current price action is overbought based on Rsi indicator however the buying momentum is staying solid, look for price to continue leading into earnings after market close on tuesday. Of the last 16/26 bullish weekly candlebars price has consecutively made higher highs with roughly 38% bearish or selling pressure within that timeframe. Based on the current up...
2024 Trading Challenge Entry #2: Diary of an Option Trader
💡 Trade Overview:
I noticed LLY soaring on the TradingView stock heatmap today. Observing the monthly chart of AMEX:XLE (healthcare sector), it has been mostly sideways for years. However, in the past two days, NYSE:LLY has demonstrated strong bullish movement with increasing volume, indicating a...
Let"s have a look at LLY chart on the 4 hours time frame. LLY has been in upsloping channel. And the price has been creating higher lows and higher highs. We expect the price to retest upsloping support and to continue the upward trajectory. The long position can be taken at the upsloping support and target would be at the upsloping resistance.
Good luck
══════════════════════════════
Since 2014, my markets approach is to spot
trading opportunities based solely on the
development of
CLASSICAL CHART PATTERNS
🤝Let’s learn and grow together 🤝
══════════════════════════════
Hello Traders ✌
After a careful consideration I came to the conclusion that:
- it is crucial to be quick in alerting you with all the...
NYSE:LLY Double Top Pierce A double top is a bearish reversal pattern in technical analysis that often signals a potential trend reversal in an asset's price. This pattern typically occurs after an uptrend and is identified by two peaks at approximately the same price level, separated by a trough or a pullback.
Here's a breakdown of the double top pattern:
1....
Eli Lilly spent the fourth quarter consolidating gains, and now trend followers may expect further upside.
The first pattern on today’s chart is the falling trendline along the peaks of November and December. Prices tried to fight above that resistance yesterday, creating potential for a breakout.
The pharma giant also pushed above its 50-day simple moving...
The FDA has approved a new drug, Zepbound, from Lilly (Eli) & Co, which will be used to treat obesity. According to the World Health Organization, nearly 3 million people die from obesity annually worldwide. Therefore, Zepbound is expected to be in demand, allowing the issuer to increase its revenue while maintaining current profitability levels. According to...
fundamentally sound as it addresses world problems
in the field of science medicine
it acquires great companies to grow its portfolio
and price wise lets investors get out at premium
yet provides ample time to those who are patient to accumulate during down years
impressive board
leadership is topnotch
if you missed the bottom and fomo in at the top or...
Eli Lilly (LLY) has been on an incredible run ever since our March 01 buy signal (see chart below) that even broke above Channel Up:
We have been strong supporters of the company's fundamentals and those are translated into strong technical bullish patters, offering solid buy opportunities. Another such opportunity exists now as the price is trading around...
LLY is holding the 1D MA50 on a neutral 1D technical outlook (RSI = 47.021, MACD = 2.060, ADX = 24.740), which indicates a strong demand level for the stock. The 1D RSI which is under a LH trendline shows that the stock price is at a pre bullish breakout accumulation like the last week of July and early August. If it holds the line, we will buy and aim a +30% rise...
NYSE:LLY is a high performing company and my single largest holding. LLY has an incredible pipeline and a strong management team. The GLP1 weight loss medications have undeniable near term and long term potential, and there is strong optimism for the Alzheimer treatment in LLY's pipeline. We need to remain objective to the possibility that the market has priced...
The tenken sen pointing upwards which actually indicates more on positive bullish bias while the kijun sen acts as strong support and remain flat which indicates a volatility throughout the development of the trend while the cloud is slightly incline and both span a and b were actually pointing upwards which could be interpret as an healthy bullish outcome for the...
Overview:
Eli Lilly and Company, a global pharmaceutical leader, is known for its extensive range of human pharmaceuticals. Founded in 1876 and headquartered in Indianapolis, LLY focuses on discovering, developing, and marketing pharmaceuticals worldwide.
Key Financials:
As of December 31, 2022, LLY's total assets stood at $49.49 billion, with a...
I guess the sky is the limit with LLY.
Earnings received well even though negative on EPS and a EPS miss.
Price appeared to be forming an M pattern but has made another leg up.
Resistance overhead.
No recommendation.
BEWARE of the dog, but that cat can be shady too (o:
